As of 3:59pm ET
| +0.3532 / +0.93%|
The 18 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 35.75, with a high estimate of 43.12 and a low estimate of 30.92. The median estimate represents a -7.08% decrease from the last price of 38.47.
The current consensus among 19 polled investment analysts is to Sell stock in Novozymes A/S. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.